People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Rachel Norris, MD ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Spravato was already available in the market before today's FDA approval and has already proven to be a financial success for ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...